On November 2, 2023 Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets, reported that the company will present the initial clinical data for its lead drug candidate, ELA026, in a poster at the American Society of Hematology (ASH) (Free ASH Whitepaper) annual meeting being held in San Diego, California, December 9-12, 2023 (Press release, Electra Therapeutics, NOV 2, 2023, View Source [SID1234636755]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
ELA026 is a monoclonal antibody that targets signal regulatory protein-α/β1/γ (SIRP) to enable precise depletion of pathological immune cells. ELA026 is currently in a Phase 1b clinical study in patients with secondary hemophagocytic lymphohistiocytosis (sHLH), a life-threatening inflammatory disease.
Details of the poster presentations are as follows:
Title: A Phase 1b Study of ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, in Patients with Newly Diagnosed and Previously Treated Secondary Hemophagocytic Lymphohistiocytosis
Session Name: 201. Granulocytes, Monocytes, and Macrophages: Poster I
Session Date and Time: Saturday, December 9, 2023, 5:30 – 7:30 p.m.
Location: San Diego Convention Center, Halls G-H
Publication Number: 1162
About Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Secondary hemophagocytic lymphohistiocytosis (sHLH) is a life-threatening hyperinflammatory condition for which there is no approved treatment. sHLH can be triggered by cancer, immunotherapy, infection, or an autoimmune disease. Once triggered, sHLH requires immediate intervention. Without treatment, it can rapidly progress from symptoms such as persistent fever, hepatomegaly and/or splenomegaly, and cytopenias, to multi-organ failure and death. Even with the current use of off-label treatments that have toxicity challenges and limited efficacy, sHLH remains fatal in approximately 60% of adults within 3.5 years.